Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biotime Inc (NY: BTX )

0.9199 USD UNCHANGED
Last Price Updated: 8:00 PM EDT, Aug 9, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.9199
Bid (Size) 0.5000 (1)
Ask (Size) 1.020 (6)
Prev. Close 0.9199
Today's Range 0.9199 - 0.9199
52wk Range N/A - N/A
Shares Outstanding 126,873,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating results for the second... 
From Business Wire News Releases
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it will report its second quarter 2019... 
From Business Wire News Releases

Performance

More News

Read More
BioTime Announces Name Change to Lineage Cell Therapeutics
From Business Wire News Releases
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
From Business Wire News Releases
BioTime Conducts Sale of Shares in OncoCyte Corporation
From Business Wire News Releases
BioTime Announces Appointment of General Counsel
From Business Wire News Releases
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
From Business Wire News Releases
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
From Business Wire News Releases
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
From Business Wire News Releases
BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
From Business Wire News Releases
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.